Day: February 1, 2021

Dorel Announces Increase in Purchase Price for Going-Private Transaction

Written by Customer Service on February 1, 2021. Posted in Public Companies.

– Purchase price increased to C$16.00 in cash per shareMONTRÉAL, Feb. 01, 2021 (GLOBE NEWSWIRE) — Dorel Industries Inc. (TSX: DII.B, DII.A) (“Dorel”) announces that it has entered into an amendment (the “Amending Agreement”) to the arrangement agreement dated November 12, 2020 (the “Arrangement Agreement”) under which a buyer group (the “Buyer Group”) led by an affiliate of funds managed by Cerberus Capital Management, L.P. (“Cerberus”) has agreed to acquire, for an increased purchase price of C$16.00 in cash per share, all of Dorel’s issued and outstanding Class A Multiple Voting Shares and Class B Subordinate Voting Shares, except for an aggregate of 4,009,410 Class A Multiple Voting Shares and 2,573,503 Class B Subordinate Voting Shares owned by Martin Schwartz, Alan Schwartz, Jeffrey Schwartz, Jeff Segel and certain...

Dorel annonce une hausse du prix d’achat dans le cadre de son opération de fermeture du capital

Written by Customer Service on February 1, 2021. Posted in Public Companies.

– Prix d’achat rehaussé à 16,00 $ CA par action au comptantMONTRÉAL, 01 févr. 2021 (GLOBE NEWSWIRE) — Les Industries Dorel Inc. (TSX : DII.B, DII.A) (« Dorel ») annonce qu’elle a conclu une modification (la « convention de modification ») à la convention d’arrangement datée du 12 novembre 2020 (la « convention d’arrangement ») aux termes de laquelle un groupe d’acheteurs (le « groupe d’acheteurs ») mené par un membre du même groupe que des fonds gérés par Cerberus Capital Management, L.P. (« Cerberus ») a convenu d’acquérir, pour un prix d’achat rehaussé de 16,00 $ CA par action au comptant, la totalité des actions à droit de vote multiple, catégorie A et des actions à droit de vote subalterne, catégorie B de Dorel émises et en circulation, à l’exception d’un total de 4 009 410 actions à droit de vote multiple, catégorie A...

Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada

Written by Customer Service on February 1, 2021. Posted in Public Companies.

Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in US and CanadaThe first toripalimab BLA to be filed with the US FDA for nasopharyngeal carcinoma later this yearSHANGHAI, China, Feb. 01, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, today announced a collaboration with Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) for the development and commercialization of toripalimab, Junshi Biosciences’ anti-PD-1 antibody, in the United States and Canada.Under the terms of the agreement, Junshi Biosciences will...

Dimensional Fund Advisors Ltd. : Form 8.3 – MARSTON’S PLC – Ordinary Shares

Written by Customer Service on February 1, 2021. Posted in Mergers And Acquisitions.

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)*Dimensional Fund Advisors Ltd. and / or its affiliates do not control voting discretion for 1,674,332 shares.All interests and all short positions should be disclosed.Details of any open stock-settled...

Aconto-udbytte for regnskabsåret 2020

Written by Customer Service on February 1, 2021. Posted in Public Companies.

København Ø, Feb. 01, 2021 (GLOBE NEWSWIRE) —Bestyrelsen har vedtaget at foretage aconto-udlodning i Investeringsforeningen BankInvest, som det fremgår af nedenstående.Udbytterne vil fragå afdelingernes/andelsklassernes indre værdi den 9. februar 2021 med valør den 11. februar 2021.Sidste dag for handel med de enkelte afdelinger/andelsklasser inklusive ret til aconto-udbytte er den 8. februar 2021. Første dag for handel med de enkelte afdelinger/andelsklasser eksklusiv ret til aconto-udbytte er den 9. februar 2021.Investorerne kan forvente at have udbyttet til rådighed på depotet den 11. februar 2021.Vi gør opmærksom på, at udbyttesatserne først er endelige, når de er vedtaget på foreningens ordinære generalforsamling den 22. april 2021.De forventede udbyttesatser vedrørende regnskabsåret 2020 for følgende 3 børsnoterede andelsklasser...

Aconto-udbytte for regnskabsåret 2020

Written by Customer Service on February 1, 2021. Posted in Public Companies.

København Ø, Feb. 01, 2021 (GLOBE NEWSWIRE) —Bestyrelsen har vedtaget at foretage aconto-udlodning i Kapitalforeningen BankInvest Select som det fremgår af nedenstående.Udbytterne vil fragå afdelingernes indre værdi den 9. februar 2021 med valør den 11. februar 2021.Sidste dag for handel med de enkelte afdelinger/andelsklasser inklusive ret til aconto-udbytte er den 8. februar 2021. Første dag for handel med de enkelte afdelinger/andelsklasser eksklusiv ret til aconto-udbytte er den 9. februar 2021.Investorerne kan forvente at have udbyttet til rådighed på depotet den 11. februar 2021.Vi gør opmærksom på, at udbyttesatserne først er endelige, når de er vedtaget på foreningens ordinære generalforsamling den 22. april 2021.Venlig hilsenBI Management A/S

Gold Standard Ventures Plan of Operations Ruled Complete by Bureau of Land Management

Written by Customer Service on February 1, 2021. Posted in Public Companies.

VANCOUVER, British Columbia, Feb. 01, 2021 (GLOBE NEWSWIRE) — Gold Standard Ventures Corp. (NYSE AMERICAN: GSV) (TSX: GSV) (“Gold Standard” or the “Company”) announced today its recently submitted Plan of Operations, outlining the Company’s plans to build and operate the South Railroad Project (“SRP”), has been ruled complete by the Bureau of Land Management Nevada (“BLM”). This ruling is an important step in the SRP permitting process.Having the Plan of Operations ruled complete by the BLM allows the Company to commence the Environmental Impact Statement (“EIS”) process pursuant to the National Environmental Policy Act. Under current guidelines and taking into account the assumptions set out in the Plan of Operations, the EIS process is estimated to take between 12 to 18 months to complete.“This is a key milestone for Gold Standard...

AnPac Bio Granted a New US patent on Novel Medical Device for Multi-Cancer Detection

Written by Customer Service on February 1, 2021. Posted in Public Companies.

SAN JOSE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that a new U.S. patent titled “Apparatus for Detecting Tumor Cells” (patent number 10,895,573) was granted to the Company by the United States Patent and Trademark Office on January 19, 2021, AnPac Bio’s 20th patent granted in the U.S. The patent contains 38 claims and covers a range of novel features for multi-cancer detection, which has become increasingly important, and covers the cancer detection apparatus, components of the apparatus, reagents, detection mechanisms, and a wide range of detection parameters, including bio-physical properties.AnPac Bio has...

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange

Written by Customer Service on February 1, 2021. Posted in Public Companies.

DENVER, Feb. 01, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it has received Conditional Approval to migrate and uplist its common shares with the NEO Exchange (“NEO”). Final approval is subject to the Company fulfilling all of NEO’s listing requirements.With the impending migration from the CSE to the NEO, the Company is positioning its common shares to be traded on a senior exchange in Canada, providing exposure to an increased number of retail and institutional investors.“The NEO is a senior stock exchange which offers a highly personalized approach...

Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis

Written by Customer Service on February 1, 2021. Posted in Public Companies.

Intramuscular injection PLEGRIDY (peginterferon beta-1a) is now approved in the U.S. and the European Union, offering individuals with relapsing multiple sclerosis (MS) a treatment option with significantly reduced injection site reactionsPLEGRIDY has a well-characterized safety and efficacy profile with a proven ability to reduce relapses and delay disability progressionTreatment access and options have become increasingly important for MS patients in the COVID-19 environmentCAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of administration for PLEGRIDY® (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). The new IM administration offers people living...

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28

Day: February 1, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals